Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 95 peer-reviewed journal articles Updated
Medical Oncology · HER2-Negative Breast Cancer

HER2-Negative Breast Cancer: A Patient Guide

At a Glance

HER2-negative breast cancer does not have high levels of the HER2 protein. It includes hormone receptor-positive and triple-negative disease, and treatment depends on subtype and stage; options may include hormone therapy, chemotherapy, surgery, radiation, immunotherapy, or targeted drugs.

HER2-negative breast cancer is the most common form of breast cancer, accounting for the vast majority of all cases [1]. While the term “negative” might sound like a lack of information, it is actually a vital piece of your diagnosis that describes the biological makeup of the cancer cells. Specifically, it means your cancer does not have high levels of the HER2 protein, which can cause cells to grow and divide more rapidly [2]. Knowing that HER2 is not driving the cancer allows your care team to focus on the other biological pathways that may be fueling it, ensuring you receive the most effective treatments while avoiding those that would not work for your specific type [3].

This diagnosis is not a single disease, but rather a broad category that splits into two primary paths based on whether the cancer cells have receptors for hormones [4]. The first and most common path is Hormone Receptor-Positive (HR+) breast cancer, where the cancer uses estrogen or progesterone to grow [5]. The second path is Triple-Negative Breast Cancer (TNBC), which lacks receptors for estrogen, progesterone, and HER2 [6]. Because these two subtypes are biologically different, they are treated in very different ways: HR+ cancer relies heavily on endocrine therapy (hormone therapy) to block those growth signals, while early-stage TNBC often requires a combination of surgery and chemotherapy, and in high-risk early-stage or specific metastatic cases, immunotherapy [3][7].

In recent years, the understanding of HER2-negative breast cancer has evolved even further with the recognition of HER2-low and HER2-ultralow statuses [2][8]. These terms describe tumors that have a tiny amount of the HER2 protein—not enough to be called “HER2-positive,” but enough to be targeted by a newer class of drugs called antibody-drug conjugates (ADCs) in specific advanced or metastatic settings [9]. ADCs are designed to preferentially deliver potent chemotherapy directly to the cancer cells, though they still circulate through the body and can cause serious side effects [10].

Your diagnosis is the starting point for a highly personalized plan designed specifically for the unique characteristics of your tumor [11]. While the biological details can feel complex, they are the tools that allow modern medicine to move away from a “one-size-fits-all” approach [12]. With the rapid advancement of targeted therapies, immunotherapies, and surgical techniques, there are now more ways than ever to treat HER2-negative breast cancer effectively, focusing on both controlling the disease and maintaining your quality of life [13][14].

In this guide

6 chapters

01

Understanding Your HER2-Negative Diagnosis

Learn what HER2-negative breast cancer means, how IHC and FISH tests classify it, and how HR-positive, triple-negative, and HER2-low results affect care.

02

Decoding Your Pathology and Biomarker Report

Learn how to read a HER2-negative breast cancer pathology report, including ER, PR, HER2, Ki-67, BRCA testing, tumor grade, margins, and lymph node status.

03

Staging and Genomic Risk Assessment

Learn how TNM stage, tumor grade, Oncotype DX, and MammaPrint help guide chemotherapy decisions in HR-positive and triple-negative HER2-negative breast cancer.

04

Treating HR-Positive/HER2-Negative Breast Cancer

Learn how HR-positive/HER2-negative breast cancer is treated, from surgery and endocrine therapy to CDK4/6 inhibitors, biomarker-guided drugs, and ADCs.

05

Treating Triple-Negative Breast Cancer (TNBC)

Learn how triple-negative breast cancer is treated, including neoadjuvant therapy, pembrolizumab, surgery, and options for residual or metastatic disease.

06

Long-Term Monitoring and Living Well

Learn how to stay safe and well with HER2-negative breast cancer, including red-flag symptoms, medication monitoring, bone health, scans, and emotional support.

Common questions in this guide

What does HER2-negative breast cancer mean?
HER2-negative means the cancer cells do not have high levels of the HER2 protein, which can promote faster cell growth. It is a broad category that includes hormone receptor-positive breast cancer and triple-negative breast cancer, so the HER2 result is only one part of the diagnosis.
Is HER2-negative breast cancer the same as triple-negative breast cancer?
No. Triple-negative breast cancer is one type of HER2-negative breast cancer because it lacks HER2 as well as estrogen and progesterone receptors. Other HER2-negative tumors are hormone receptor-positive and may respond to hormone-blocking treatment.
What do HER2-low and HER2-ultralow mean?
These terms describe tumors with a small amount of HER2 that is not high enough to be classified as HER2-positive. In some advanced or metastatic situations, this level may make a person eligible for an antibody-drug conjugate, a medicine designed to carry chemotherapy toward cancer cells. Eligibility depends on the exact test result and treatment setting.
How is HER2-negative breast cancer treated?
Treatment depends on whether the cancer is hormone receptor-positive or triple-negative, as well as its stage and other features. Care may include surgery, radiation, chemotherapy, hormone-blocking treatment, immunotherapy, or targeted medicines; not every person needs all of these. Your breast cancer team uses your results to decide the sequence and combination.
What test results should I discuss with my breast cancer team?
Ask about your estrogen and progesterone receptor percentages, your exact HER2 score, and whether the result is considered HER2-low or HER2-ultralow. Depending on your diagnosis, the team may also discuss genetic testing for BRCA mutations or a genomic risk test such as Oncotype DX. These results can help guide treatment decisions, but their usefulness depends on the cancer's subtype and stage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my exact percentages for ER and PR, and what was my specific HER2 score?
  2. 2.Does my HER2 result fall into the 'HER2-low' or 'HER2-ultralow' category, and how does that affect my access to newer treatments?
  3. 3.Based on my specific subtype and stage, what is the sequence of my treatment plan—when do surgery, radiation, and medication happen?
  4. 4.Should we consider any genetic testing for BRCA mutations or genomic risk assays like Oncotype DX for my tumor?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.

    Huppert LA, Gumusay O, Idossa D, Rugo HS

    CA: a cancer journal for clinicians 2023; (73(5)):480-515 doi:10.3322/caac.21777.

    PMID: 36939293
  2. 2

    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.

    Wolff AC, Somerfield MR, Dowsett M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(22)):3867-3872 doi:10.1200/JCO.22.02864.

    PMID: 37284804
  3. 3

    Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

    Caswell-Jin JL, Somerfield MR, Khan MA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; 101200JCO2602034 doi:10.1200/JCO-26-02034.

    PMID: 42647767
  4. 4

    Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms.

    Khadela A, Morakhia KR, Shah NH, et al.

    Journal of drug targeting 2025; (33(10)):1743-1756 doi:10.1080/1061186X.2025.2525372.

    PMID: 40566991
  5. 5

    A perspective on anti-EGFR therapies targeting triple-negative breast cancer.

    Nakai K, Hung MC, Yamaguchi H

    American journal of cancer research 2016; (6(8)):1609-23.

    PMID: 27648353
  6. 6

    Triple negative breast cancer: Pitfalls and progress.

    Zagami P, Carey LA

    NPJ breast cancer 2022; (8(1)):95 doi:10.1038/s41523-022-00468-0.

    PMID: 35987766
  7. 7

    Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.

    Mohamed A, Kruse M, Tran J

    Expert review of anticancer therapy 2023; (23(10)):1071-1084 doi:10.1080/14737140.2023.2262764.

    PMID: 37747062
  8. 8

    International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories.

    Rakha EA, Tan PH, Van Bockstal MR, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2026; (39(1)):100925 doi:10.1016/j.modpat.2025.100925.

    PMID: 41167529
  9. 9

    US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.

    Dilawari A, Zhang H, Shah M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(26)):2942-2951 doi:10.1200/JCO-25-00812.

    PMID: 40763319
  10. 10

    Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

    Bardia A, Hu X, Dent R, et al.

    The New England journal of medicine 2024; (391(22)):2110-2122 doi:10.1056/NEJMoa2407086.

    PMID: 39282896
  11. 11

    Navigating Treatment Decisions in Early-Stage Hormone Receptor-Positive Breast Cancer.

    Amir E, Kristoff T, Blaha C, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2026; (46(3)):e520488 doi:10.1200/EDBK-26-520488.

    PMID: 42208010
  12. 12

    Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

    Singareeka Raghavendra A, Damodaran S, Barcenas CH, et al.

    CA: a cancer journal for clinicians 2026; (76(1)):e70055 doi:10.3322/caac.70055.

    PMID: 41524544
  13. 13

    Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

    Schmid P, Cortes J, Dent R, et al.

    The New England journal of medicine 2024; (391(21)):1981-1991 doi:10.1056/NEJMoa2409932.

    PMID: 39282906
  14. 14

    Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.

    Burstein HJ, Somerfield MR, Barton DL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(35)):3959-3977 doi:10.1200/JCO.21.01392.

    PMID: 34324367

This page is for informational purposes only and does not constitute medical advice. Your breast cancer team can interpret your receptor results and discuss the treatment plan best suited to your situation.

Get notified when new evidence is published on Her2-receptor negative breast cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.